Our study utilized the most recent data available to provide contemporary assessment on the timing associated with biomarker testing (both PD-L1 and NGS) from collection of tumor specimen to receipt of test results among patients with METex14 aNSCLC. The gene discussed is CD274; the disease is neoplasm.